Results 231 to 240 of about 283,147 (286)

Pharmacokinetic profiling of imatinib in relation to CYP3A4 activity in leukaemia patients

British Journal of Clinical Pharmacology, EarlyView.
Aim Imatinib pharmacokinetics exhibit large interindividual variability because of differences in CYP3A4 activity—the main imatinib‐metabolizing enzyme. While therapeutic drug monitoring is effective, it requires steady‐state conditions and frequent sampling.
Anna Sofie Buhl Rasmussen, Mathilde Rønne Koch, Cecilie Utke Rank, Christen Lykkegaard Andersen, Allan Weimann, Maria Thastrup, Tianwu Yang, Trine Meldgaard Lund, Ib Jarle Christensen, Flemming Nielsen, Tore Bjerregaard Stage, Sara Bisgaard Jensen, Mette Klarskov Andersen, Kjeld Schmiegelow, Kim Dalhoff   +14 more
wiley   +1 more source

The Effect of Efavirenz and Rufinamide on the Pharmacokinetics and Safety of Quizartinib: Two Phase 1 Studies in Healthy Participants. [PDF]

Clin Transl Sci
Yoo Y, Zahir H, Inaba S, Koo K, Garimella T, Abutarif M, Zheng M, Kamiyama E, Xu Y.   +8 more
europepmc   +1 more source

Evaluation of a pantoprazole and 4‐desmethylpantoprazole‐sulfate metabolic ratio as a novel CYP2C19 phenotyping method

British Journal of Clinical Pharmacology, EarlyView.
Aims CYP2C19 is one of the most important pharmacogenes, and its activity is highly variable due to factors such as genetics or drug–drug interactions. Due to the lack of an appropriate endogenous CYP2C19 biomarker, surrogate methods to assess its activity are warranted.
Julian Peter Müller, Vladimir N. Belov, Sabrina Yamoune, Bob Miller, Mohammed Hasoumi, Jolanta Tupiec, Thea Laurentius, L. Cornelius Bollheimer, Julia C. Stingl, Katja S. Just   +9 more
wiley   +1 more source

Elucidation of the Guanitrypmycin Biosynthetic Pathway in <i>Kitasatospora azatica</i> Leading to Structure Revision and Reassignment. [PDF]

J Nat Prod
Mann P, Li SM.
europepmc   +1 more source

First‐in‐human, phase I, randomized, safety, pharmacokinetic, food‐effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC‐1801

British Journal of Clinical Pharmacology, EarlyView.
Aim The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), food‐effect (FE) and pharmacodynamics (PD) of an oral tyrosine kinase‐2 (TYK2)/Janus kinase‐1 (JAK1) inhibitor, SDC‐1801, in healthy adult participants. Methods This first‐in‐human study randomized 95 male and female participants.
Chris Brearley, Sam Francis, John Reader, Judi Proctor   +3 more
wiley   +1 more source

Development and Validation of a Quantitative LC-MS/MS Method for Measuring CYP4V2 Enzyme Activity via 12-Hydroxylauric Acid in rAAV-hCYP4V2 Gene Therapy Products. [PDF]

Molecules
Ren G, Qin X, Li Y, Fan W, Luo W, Cao Y, Wang Y, Zhou Y, Liang C.   +8 more
europepmc   +1 more source

The effect of mild and moderate hepatic impairment on the pharmacokinetics, safety and tolerability of balcinrenone

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Balcinrenone (previously AZD9977) is a novel selective non‐steroidal mineralocorticoid receptor antagonist (MRA) with a differential mechanism of action relative to approved MRAs. The aim of this trial was to assess the pharmacokinetics, safety and tolerability of balcinrenone in participants with mild and moderate hepatic impairment ...
Anna L. Eriksson, Deeyen Karsanji, Bonifride Tuyishimire, Joanna Parkinson, Maria Heijer, Tadeusz Pawlik, Judith Hartleib‐Geschwindner, Maria Leonsson‐Zachrisson, Hans Ericsson   +8 more
wiley   +1 more source

Boric Acid Mitigates Alcohol-Induced Renal Podocyte Injury, Apoptosis, and Oxidative Stress in HBV Transgenic Mice. [PDF]

Antioxidants (Basel)
Sevgin K, Erguven P, Tanrikulu-Kucuk S, Degirmencioglu S, Cetinalp P, Aksu S, Gun-Atak P, Sogut I.   +7 more
europepmc   +1 more source

Development of a population pharmacokinetic model using combined paediatric and adult data for four pulmonary arterial hypertension drugs

British Journal of Clinical Pharmacology, EarlyView.
Aims Pulmonary arterial hypertension (PAH) is a syndrome characterized by elevated pulmonary artery pressure. We developed a population pharmacokinetic (PPK) model using combined plasma drug concentration data from Japanese paediatric (<15 years) and adult (≥15 years) patients with PAH to investigate the pharmacokinetic characteristics of PAH ...
Motoyasu Miura, Shimako Tanaka, Ririka Aihara, Shun Yamamoto, Yasumi Nakashima, Yasuharu Kashiwagura, Akio Hakamata, Sachiko Miyakawa, Mariko Tatsuguchi, Keiichi Odagiri, Noriyuki Namiki, Naoki Inui, Hiroshi Watanabe, Shinya Uchida   +13 more
wiley   +1 more source

Lycopene Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease via PINK1/Parkin-Mediated Mitophagy Activation and Apoptosis Attenuation. [PDF]

Antioxidants (Basel)
Xu Z, Wu X, Ye L, Li Z, Zhao J, Zhang Z, Sun Y.   +6 more
europepmc   +1 more source